tbuckley/cabot-search huggingface dataset:
P2.01-070 FAACT- Anorexia Cachexia Scale: Cut-Off Value for the Anorexia Diagnosis in NSCLC Patients
Authors: J. Turcott, L. Ramirez-Tirado, L. Oñate-Ocaña, D. Flores-Estrada, Z. Zatarain-Barron, G. Soca-Chafre, O. Arrieta
Journal: Journal of Thoracic Oncology (2017)
P1.02-068 Effects of Pirfenidone Targeting EMT and Tumor-Stroma Interaction as Novel Treatment for Non-Small Cell Lung Cancer
Authors: A. Fujiwara, Y. Shintani, S. Funaki, T. Kawamura, R. Kanzaki, E. Fukui, M. Minami, M. Okumura
Journal: Journal of Thoracic Oncology (2017)
OA 02.05 RESPECT-MESO: An International Randomized Controlled Trial to Assess Early Specialist Palliative Care in Malignant Pleural Mesothelioma
Authors: F. Brims, S. Gunatilake, I. Lawrie, L. Marshall, C. Fogg, N. Maskell, K. Forbes, N. Rahman, S. Morris, S. Gerry, A. Chauhan
Journal: Journal of Thoracic Oncology (2017)
P1.03-048 miR-34a and the Micromanagement of Cancer Stemness and Resistance in NSCLC. Does It Hold Therapeutic Benefit?
Authors: L. Mac Donagh, S. Gray, M. Gallagher, B. Ffrench, C. Gasch, S. Finn, S. Cuffe, K. O’Byrne, M. Barr
Journal: Journal of Thoracic Oncology (2017)
Re: Woonyoung Choi, Andrea Ochoa, David J. McConkey, et al. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. Eur Urol 2017;72:354–65
Authors: Joshua A. Linscott, Angela B. Smith, Jesse D. Sammon
Journal: European Urology (2017)
PUB071 Circulating Programmed Death Ligand-1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)
Authors: S. Vecchiarelli, A. D'Incecco, G. Minuti, M. Gallo, A. De Luca, L. Landi, C. Bennati, M. Spreafico, M. D'Arcangelo, L. Attilia, V. Mazza, N. Normanno, F. Cappuzzo
Journal: Journal of Thoracic Oncology (2017)
P1.16-003 Learning Curve for Adoption of Robotic Lobectomy for Early Stage Non-Small Cell Lung Cancer by a Thoracic Surgeon Experienced in Open Lobectomy
Authors: S. Gallagher, A. Abolhoda, V. Kirkpatrick, A. Saffarzadeh, M. Thein, S. Wilson
Journal: Journal of Thoracic Oncology (2017)
P1.07-038 The Potential Clinical Application of Comprehensive Genomic Profiling in Targeted Therapy and Immunotherapy of Lung Cancer
Authors: M. Chen, J. Hu, L. Wang, G. Li, C. Liu, M. Wang, L. Dai, W. Wang, G. Chirn, S. Mu, L. Chen, J. Hu, M. Yao, K. Wang
Journal: Journal of Thoracic Oncology (2017)
ACTR-95. HYPOXIA ACTIVATED EVOPHOSPHAMIDE (TH-302) FOR RECURRENT GBM FOLLOWING BEVACIZUMAB FAILURE, A MULTICENTER PHASE II STUDY
Authors: Andrew Brenner, David Reardon, Patrick Wen, Peter Fox, Shiliang Huang, Mark Muzi, Yichu Liu, Eudocia Lee
Journal: Neuro-Oncology (2017)

TH-302 (evophosphamide) is a hypoxia-activated prodrug that, when activated in hypoxic conditions (<0.5% O2), releases the bis-alkylating agent bromo-isophosphoramide mustard (Br-IPM), which can then act as a DNA crosslinking agent. In vivo, TH-302 has shown to potentiate the anti-tumor efficacy of other antiangiogenic agents. Pur prior phase 1 study with dose expansion showed preliminary activity with a 24% objective response rate and a 26% PFS rate at 4 months. A multicenter, single-arm, two-stage prospective study, non-blinded with combination therapy with bevacizumab at 10 mg/kg intravenously (IV) every 2 weeks and TH-302 at 670 mg/m2 IV every 2 weeks, in 6 week cycles, until disease progression. The primary endpoint is progression free survival at 4 months. Patients underwent baseline assessment for hypoxic burden by 18F-misonidazole PET, dynamic susceptibility contrast (DSC) perfusion imaging, and serum sampling for biomarker analysis. Accrual is complete with 36 patients receving study drug. Treatment was well tolerated, with adverse events as expected and the most common toxicity rash along the perineum. While 6 patients remain on treatment, 6 of the required 7 PFS4 events have occured with one more needed to meet the designated positive endpoint. Correlation with imaging and serum biomarkers is ongoing and may help further define the subset of patients with the greatest benefit. Evofosfamide appears to have clinically meaningful activity in bevacizumab refractory glioblatoma. Results will be updated.
Differential preventive activity of sulindac and atorvastatin in Apc<sup>+/Min-FCCC</sup>mice with or without colorectal adenomas
Authors: Wen-Chi L Chang, Christina Jackson, Stacy Riel, Harry S Cooper, Karthik Devarajan, Harvey H Hensley, Yan Zhou, Lisa A Vanderveer, Minhhuyen T Nguyen, Margie L Clapper
Journal: Gut (2017)

Objective The response of subjects to preventive intervention is heterogeneous. The goal of this study was to determine if the efficacy of a chemopreventive agent differs in non-tumour-bearing animals versus those with colorectal tumours. Sulindac and/or atorvastatin was administered to Apc +/Min-FCCC mice with known tumour-bearing status at treatment initiation. Design Male mice (6–8 weeks old) underwent colonoscopy and received control chow or chow with sulindac (300 ppm), atorvastatin (100 ppm) or sulindac/atorvastatin. Tissues were collected from mice treated for 14 weeks (histopathology) or 7 days (gene expression). Cell cycle analyses were performed on SW480 colon carcinoma cells treated with sulindac, atorvastatin or both. Results The multiplicity of colorectal adenomas in untreated mice bearing tumours at baseline was 3.6-fold higher than that of mice that were tumour free at baseline (P=0.002). Atorvastatin completely inhibited the formation of microadenomas in mice that were tumour free at baseline (P=0.018) and altered the expression of genes associated with stem/progenitor cells. Treatment of tumour-bearing mice with sulindac/atorvastatin led to a 43% reduction in the multiplicity of colorectal adenomas versus untreated tumour-bearing mice (P=0.049). Sulindac/atorvastatin increased the expression of Hoxb13 and Rprm significantly, suggesting the importance of cell cycle regulation in tumour inhibition. Treatment of SW480 cells with sulindac/atorvastatin led to cell cycle arrest (G0/G1). Conclusions The tumour status of animals at treatment initiation dictates response to therapeutic intervention. Atorvastatin eliminated microadenomas in tumour-free mice. The tumour inhibition observed with Sul/Atorva in tumour-bearing mice was greater than that achieved with each agent.
Legionelosis en turistas europeos asociada a viajes a España
Authors: A Galmés Truyols, J. F. Martinez Navarro
Journal: Eurosurveillance (1997)

La enfermedad del legionario asociada a viajes ha constituido una preocupacion para algunos paises europeos desde la segunda mitad de los anos 80. Unos, los paises del norte, a causa de la afectacion de sus ciudadanos durante sus viajes y otros, los mediterraneos, por el efecto que sobre su economia podra tener una incidencia elevada de la enfermedad entre los turistas. Por ello se creo el European Working Group for Legionella Infections (EWGLI ) (1) y los casos empezaron a ser notificados desde los paises de procedencia a los receptores de turismo a traves del Centro Colaborador de la OMS de Estocolmo.
IMMU-17. REDUCING THE EX VIVO MANUFACTURING TIME OF EGFRVIII-SPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS IMPROVES PHENOTYPE AND DEMONSTRATES POTENT ANTI-GLIOMA FUNCTION IN VIVO
Authors: Ryuma Tanaka, Hillary Caruso, Xiaoyang Ling, Amer Najjar, Amy Heimberger
Journal: Neuro-Oncology (2017)

Chimeric antigen receptor (CAR) T-cell therapy for glioma has been developed that targets EGFRvIII, HER2, EphA2, and IL13Rα2 antigens. Epidermal growth factor receptor variant III (EGFRvIII) is an attractive target for CAR therapy because its expression is tumor-restricted. Non-viral manufacturing of CAR T cells via Sleeping Beauty transposition is cost effective and reduces risk of insertional mutagenesis from viral transduction. However, the current gold standard methodology requires ex vivo expansion on artificial antigen-presenting cells (AaPCs) for 4 weeks to eliminate competing NK cells from culture and to generate sufficient cell numbers for clinical application. We monitored phenotypic changes of EGFRvIII-specific CAR T cells over the course of ex vivo manufacturing and found significantly increased expression of the exhaustion markers such as PD-1, PD-L1, TIM-3, and LAG-3 after two weeks of culture, which continued to rise over time. To reduce the culture time required to generate the CAR T cell population, we selected for T cells in peripheral blood mononuclear cells prior to CAR modification (to eliminate the NK cell population) and were able to generate a CAR+ T cell population with comparable CAR expression and cell numbers in two weeks—half the time required by the standard protocol and with lower expression of exhaustion markers. We treated mice bearing established orthotopic EGFRvIII+ U87 gliomas with EGFRvIII-specific CAR T cells derived using the expedited approach and showed significant suppression of tumor growth after one treatment. Thus, T-cell selection prior to CAR modification produces CAR T cells with an improved phenotype and potent in vivo function in less time, which will decrease the wait time for patients.
Les Staphylococccus aureus résistants à la méthicilline (MRSA) dans la population générale
Authors: J H T Wagenvoort, M Kepers-Rietrae
Journal: Eurosurveillance (1997)

Les Staphylococcus aureus resistants a la methicilline (MRSA) associes a des infections nosocomiales sont particulierement bien connus (1) mais on sait egalement qu'ils sont a l'origine d'infections dans la population generale (2). Nous avons defini les cas d'infection a MRSA acquise dans la population generale par la detection d'une souche de MRSA chez une personne n'ayant pas frequente de milieu hospitalier pour un sejour ou une consultation dans les 12 derniers mois et n'ayant jamais eu d'infection/contamination par MRSA documentee. Jusqu'a present, ces cas ont ete rarement rapportes en Europe (1).
Long-Term Outcomes in Patients With Type 2 Myocardial Infarction and Myocardial Injury
Authors: Andrew R. Chapman, Anoop S.V. Shah, Kuan Ken Lee, Atul Anand, Oliver Francis, Philip Adamson, David A. McAllister, Fiona E. Strachan, David E. Newby, Nicholas L. Mills
Journal: Circulation (2017)

Type 2 myocardial infarction and myocardial injury are common in clinical practice, but long-term consequences are uncertain. We aimed to define long-term outcomes and explore risk stratification in patients with type 2 myocardial infarction and myocardial injury.
P3.02-071 Statins May Improve the Prognosis of Patients with Lung Adenocarcinoma by Suppressing Mutant p53-Induced EMT
Authors: S. Nishikawa, T. Menju, T. Soawa, K. Takahashi, R. Miyata, H. Ishikawa, M. Hamaji, H. Motoyama, A. Aoyama, T. Sato, C. Fengshi, M. Sonobe, H. Date
Journal: Journal of Thoracic Oncology (2017)
OA 07.07 Inhibition of the Novel Oncogene ELF3 Abolishes Lung Adenocarcinoma Growth
Authors: K. Enfield, E. Marshall, K. Ng, C. Anderson, S. Rahmati, S. Lam, C. Macaulay, W. Lockwood, A. Karsan, I. Jurisica, W. Lam
Journal: Journal of Thoracic Oncology (2017)
P1.03-011 Clinical Outcomes Correlated with Percentage of Positive Anaplastic-Lymphoma Kinase Cells Tested by FISH Analysis in NSCLC
Authors: K. Clarke, H. Dickinson, K. Spencer, E. Verghese, K. Franks, S. Sabir, R. Bayliss
Journal: Journal of Thoracic Oncology (2017)
Abstract 20032: Outpatient Exposure to Potentially Harmful Drugs in Patients With Heart Failure
Authors: Paulino Alvarez, Cecilia Ganduglia, David Putney, Jerry D Estep
Journal: Circulation (2015)

Background: Several drugs have the potential to cause or decompensate heart failure (HF). Objective: To evaluate the frequency of potentially harmful drug exposure after hospital discharge in patients with heart failure. Methods: This was a retrospective analysis of Blue Cross Blue Shield of Texas (BCBSTX) claims data (2008-2013) which contains information for medical and pharmacy services. We included patients with at least one admission with a primary or secondary diagnosis for heart failure as defined by ICD-9 codes. We then analyzed all pharmaceutical claims for those patients as of day of discharge. Exposure to potentially harmful drugs (PHD) was defined as the use of non-steroidal anti-inflammatory agents (NSAIDS), Thiazolidinediones (TZD), Alpha-blockers (AB), Antiarrhythmic (AA) and non-dihydropyridine calcium channel blockers (non DPCCB) as recorded in pharmaceutical claims using AHFS Pharmacologic-Therapeutic Classification. Results: A total of 35317 discharges with a primary or secondary diagnosis of heart failure were identified, of which we analyzed a subset of 13,926 discharges from a total of 9,784 patients who had pharmacy coverage through BCBSTX. We found that of 5,730 (69%) had a prescription for at least one PHD after discharged. NSAIDS were the most common category 77% (4430) followed by AA 781(13.6%), non DPCCB 322 (5.6%), TZD 103 (1.8%) and AB 94 (1.6%). Most cases were recorded as new prescription claims with a relatively short interval between discharge and prescription. (Table 1) Conclusion: In patients discharged from the hospital with a primary or secondary diagnosis of heart failure, exposure to potentially harmful drugs is not uncommon, especially NSAIDS. Further research to define the consequences of this exposure is needed.
CMET-25. PROGRESSION-FREE SURVIVAL (PFS) AND SITE OF FIRST PROGRESSION IN HER2+ METASTATIC BREAST CANCER PATIENTS WITH OR WITHOUT BRAIN METASTASES: A POOLED ANALYSIS OF TUCATINIB PHASE I STUDIES
Authors: Erika Hamilton, Stacy Moulder, Cristiano Ferrario, Alison Conlin, Ian Krop, Marc Chamberlain, Todd Gray, Virginia Borges
Journal: Neuro-Oncology (2017)

Brain metastases (BM) are frequent in HER2+ metastatic breast cancer (MBC) occurring in 50% of patients and are associated with significant neurologic morbidity and mortality. Tucatinib is a highly selective irreversible oral HER2+ tyrosine kinase inhibitor that has shown promising results in HER2+ MBC both in patients with and without BM. Two Phase 1b studies of tucatinib were pooled to compare PFS and sites of relapse in patients with or without BM. 77 patients were analyzed, 50 in the 004 (tucatinib + T-DM1) and 27 in the 005 trials (tucatinib + trastuzumab + capecitabine). Patients were heavily pretreated with a median of 3 prior HER2 therapies. Four cohorts were identified: 46% (35) had systemic metastases only, 17% (13) had previously treated (RT with or without surgery) and stable BM, 19% (15) had previously treated and progressive BM and 17% (13) had asymptomatic untreated BM demonstrated by screening MRI. Median PFS across cohorts was similar and no statistically significant difference in PFS was seen when comparing the non-BM cohort to all BM cohorts. The incidence of progression in brain in patients with baseline BM was 51.2% overall compared to an 8.3% in patients without baseline BM. >50% of patients entered tucatinib studies with baseline BM, either previously treated (stable or progressive) or untreated. Patient cohorts analyzed appear to differ only in the site of disease progression. Patients without BM at baseline progress primarily in body whereas patients with baseline BM primarily mostly progress in the brain. Nonetheless, PFS is comparable across cohorts. Furthermore, patients both with and without BM have durable responses with these combination therapies following multiple lines of prior HER2 targeted therapy. These data support the use of tucatinib in both patients with and without BM in the accruing HER2CLIMB trial.
Second-line treatment efficacy in elderly vs. non-elderly advanced gastric cancer patients: an Italian multicentre real-world study
Authors: V. Fanotto, M. Uccello, L. Fornaro, L. Rimassa, F. Leone, G. Rosati, D. Santini, R. Giampieri, S. Di Donato, G. Tomasello, N. Silvestris, G. Peverelli, F. Battaglin, A. Avallone, M. Scartozzi, S. Cinieri, D. Melisi, L. Antonuzzo, A. Pellegrino, L. Gerratana, G. Aprile
Journal: Annals of Oncology (2017)
Um surto de hepatite A persistente em Puglia, Itália, 1996: inquérito epidemiológico
Authors: P L Lopalco, P Malfait, S Salmaso, C A Germinario, M Quarto, S Barbuti, R Cipriani, A Mundo, G Pesole
Journal: Eurosurveillance (1997)

Um aumento do numero de declaracoes de hepatite A foi observado na regiao de Puglia, no sudeste de Italia, no inicio do ano de 1996. Uma investigacao epidemiologica realizada em Maio de 1996 mostrou uma forte associacao entre a doenca e o consumo de mariscos crus (odds ratio (OR) = 31,8 [12,1-118]) ; o armazenamento dos mariscos, em agua do mar, no local de venda estava igualmente associado a um aumento do risco de infeccao (1). Apesar das recomendacoes que tinham sido feitas sobre a manipulacao e o consumo dos mariscos, o numero de novos casos aumentou, nos meses seguintes, em toda a regiao de Puglia, com um pico em Agosto de 1996 na provincia de Bari. Uma investigacao adicional foi efectuada para identificar outras exposicoes relevantes que pudessem ser responsaveis pela persistencia deste surto.
Margaret McCartney: General practice can’t just exclude sick people
Authors: Margaret McCartney
Journal: BMJ (2017)

GP at Hand, an NHS general practice in west London, is offering to register patients for virtual consultations. It may also permanently destabilise English general practice.

One partner of GP at Hand is Mobasher Butt, medical director of the health IT company Babylon, and the practice uses the Babylon symptom checker app. This app, the practice says, gives patients “useful medical information and accurate triage advice.”1

Interesting, because it also says that “The GP at Hand practice shall not be responsible for the artificial intelligence symptom checker which is a separate service provided by Babylon via the App.”2 The results of a pilot study of this app in north London do not yet seem to be published. Babylon has claimed to have independent evidence of safety, but I’ve yet to see it.3 Babylon says that the app “enables your purchase of healthcare and other products sold by our third party product partners.”2

GP at Hand …
Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C
Authors: Peter Buggisch, Johannes Vermehren, Stefan Mauss, Rainer Günther, Eckart Schott, Anita Pathil, Klaus Boeker, Tim Zimmermann, Gerlinde Teuber, Heike-Pfeiffer Vornkahl, Karl-Georg Simon, Claus Niederau, Heiner Wedemeyer, Stefan Zeuzem
Journal: Journal of Hepatology (2017)
P3.03-027 LKB1 Loss Is Associated with Resistance to Anti-Angiogenic Therapy in Non-Small Cell Lung Cancer Mouse Models
Authors: I. Guijarro, A. Poteete, Y. Fan, S. Cho, P. Tong, E. Roarty, M. Nilsson, J. Rodriguez-Canales, B. Mino, E. Parra Cuentas, I. Wistuba, J. Wang, J. Heymach
Journal: Journal of Thoracic Oncology (2017)
Long-term Fine Particulate Matter Exposure and Nonaccidental and Cause-specific Mortality in a Large National Cohort of Chinese Men
Authors: Peng Yin, Michael Brauer, Aaron Cohen, Richard T. Burnett, Jiangmei Liu, Yunning Liu, Ruiming Liang, Weihua Wang, Jinlei Qi, Lijun Wang, Maigeng Zhou
Journal: Environmental Health Perspectives (2017)

Background: Cohort studies in North America and western Europe have reported increased risk of mortality associated with long-term exposure to fine particles (PM2.5), but to date, no such studies have been reported in China, where higher levels of exposure are experienced. Objectives: We estimated the association between long-term exposure to PM2.5 with nonaccidental and cause-specific mortality in a cohort of Chinese men. Methods: We conducted a prospective cohort study of 189,793 men 40 y old or older during 1990–91 from 45 areas in China. Annual average PM2.5 levels for the years 1990, 1995, 2000, and 2005 were estimated for each cohort location using a combination of satellite-based estimates, chemical transport model simulations, and ground-level measurements developed for the Global Burden of Disease (GBD) 2013 study. A Cox proportional hazards regression model was used to estimate hazard ratios (HR) for nonaccidental cardiovascular disease (CVD), chronic obstructive pulmonary disease (COPD), and lung-cancer mortality. We also assessed the shape of the concentration–response relationship and compared the risk estimates with those predicted by Integrated Exposure-Response (IER) function, which incorporated estimates of mortality risk from previous cohort studies in western Europe and North America. Results: The mean level of PM2.5 exposure during 2000–2005 was 43.7 μg/m3 (ranging from 4.2 to 83.8 μg/m3). Mortality HRs (95% CI) per 10-μg/m3 increase in PM2.5 were 1.09 (1.08, 1.09) for nonaccidental causes; 1.09 (1.08, 1.10) for CVD, 1.12 (1.10, 1.13) for COPD; and 1.12 (1.07, 1.14) for lung cancer. The HR estimate from our cohort was consistently higher than IER predictions. Conclusions: Long-term exposure to PM2.5 was associated with nonaccidental, CVD, lung cancer, and COPD mortality in China. The IER estimator may underestimate the excess relative risk of cause-specific mortality due to long-term exposure to PM2.5 over the exposure range experienced in China and other low- and middle-income countries. https://doi.org/10.1289/EHP1673
Abstract 20392: In-Hospital Basic Life Support: Major Differences in Duration, Retraining Intervals, and Training Methods - A Danish Nationwide Study
Authors: Ditte K Rasmussen, Kasper G Lauridsen, Mathilde Staerk, Troels Mygind, Bo Loefgren
Journal: Circulation (2017)

Introduction:  High-quality chest compressions and early defibrillation is essential to improve survival following in-hospital cardiac arrest. Efficient training in basic life support (BLS) for clinical staff is therefore important. This study aimed to investigate duration, training methods and retraining intervals for BLS training of clinical staff in Danish hospitals.   Methods:  We included all public, somatic hospitals in Denmark with a cardiac arrest team. Online questionnaires were distributed to resuscitation officers in each hospital. Questionnaires inquired information on: A) Course duration and retraining interval, and B) Training methods and setting.   Results:  In total, 44 hospitals replied (response rate: 96%). BLS training for clinical staff was conducted in 41 hospitals (93%). Median (Q1;Q3) course duration was 1.5 (1;2.5) hours. Retraining was conducted every year (17%), every second year (56%) or every third year (20%). In 3 (7%) hospitals retraining was never conducted. Hospitals had a median of 7 (6;10) participants per instructor and a median of 6 (2;8) participants per training manikin. In 39% of hospitals half an hour or less was spent on hands-on training (median (Q1;Q3): 1 (0.5;1.5)). Hands-on training included 30:2 and compressions only CPR by 63% while 30:2 was the only method trained by 32%. Hand-on training was not offered in 5% of hospitals. Overall, 80% included training using an AED. Chest compressions were trained in bed (63%), on the floor (46%), on a table (34%) or on a gurney (29%). Backboards were used in 2% of hospitals. Work position during chest compressions was part of training, and included adjusting the bed height (70%), removing the bed rail (59%), and/or jumping onto the bed (41%). CPR feedback devices were used by 85%. An end-of-course test for BLS skills was used in 18% of hospitals.   Conclusion:  There is a major difference in duration and retraining intervals for BLS training of clinical staff in Danish hospitals. Approximately half of hospitals spent less than one hour on hands-on training. Chest compressions were practiced on different surfaces using different methods to optimize work position. Backboards are very rarely used. Most hospitals did not use end-of-course tests for BLS skills.